Anti-HIV agents. A second study confirms fat loss issues with efavirenz.
D000328:Adult; D000480:Alkynes; D048588:Benzoxazines / Q000009:adverse effects*; D018791:CD4 Lymphocyte Count; D003521:Cyclopropanes; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000008:administration & dosage; D006801:Humans; D008060:Lipodystrophy / Q000139:chemically induced*; D008297:Male; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects*; D019562:Viral Load
D000480:Alkynes; D048588:Benzoxazines; D003521:Cyclopropanes; D017320:HIV Protease Inhibitors; D018894:Reverse Transcriptase Inhibitors; C098320:efavirenz